Skip to main content

Table 1 General information of OHSS high-risk and non high-risk groups

From: Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

  OHSS high-risk groups (n = 281) OHSS non high-risk group
Letrozole group Mifepristone group GnRH-ant group Three-drug group Control group
(n = 43) (n = 51) (n = 39) (n = 28) (n = 120) (n = 4454)
Age (year) 30.6 ± 3.5 29.7 ± 4.1 29.9 ± 4.2 30.2 ± 3.8 30.1 ± 4.0 30.9 ± 3.9
BMI (kg/m2) 21.8 ± 3.3 21.5 ± 4.3 21.7 ± 3.0 21.2 ± 3.5 21.4 ± 2.9 21.3 ± 3.6
PCOS (n) 7 (16.3 %) 8 (15.7 %) 5 (12.8 %) 4 (14.3 %) 18 (15.0 %) 142 (3.2 %)
Duration of infertility (year) 4.9 ± 2.5 4.7 ± 2.8 4.6 ± 3.2 4.4 ± 3.1 4.3 ± 3.5 4.8 ± 3.6
Baseline FSH (IU/L) 5.6 ± 1.8 5.3 ± 1.7 5.9 ± 1.5 5.8 ± 1.7 6.1 ± 1.6 6.3 ± 1.5
Baseline E2 (pg/ml) 51.2 ± 19.4 49.3 ± 17.6 50.9 ± 17.8 47.4 ± 16.5 48.2 ± 18.2 46.6 ± 18.3
Duration of Gn (days) 11.1 ± 2.0 11.2 ± 1.9 10.9 ± 1.6 11.5 ± 1.8 11.3 ± 2.1 11.2 ± 2.2
Total Gn ampoules (75 IU) 24.7 ± 6.3 24.9 ± 6.8 25.3 ± 6.5 25.7 ± 6.6 25.2 ± 6.4 28.7 ± 9.8
  1. Values are means ± SD. Values in parentheses are percentages
  2. BMI body mass index, PCOS polycystic ovary syndrome FSH follical stimulation hormone, E 2 estradiol, Gn gonadotropin